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The use of high-dose chemotherapy with autologous hemagiven six cycles of chemotherapy regimen EC topoietic progenitor cell support in the treatment of breast (epirubicin (150 mg/m 2 ) and cyclophosphamide cancer has increased enormously in the last few years.
1
(1250 mg/m 2 ) on day 1). In the first cycle, 24 h after Multicyclic dose-intensive treatment offers the opportunity chemotherapy, mobilization of the peripheral blood to maximize cytotoxic dose-intensity for solid tumors. 2 For progenitor cells (PBPC) was started with growth factor the majority of drugs, myelosuppression is the initial dose-G-CSF (Neupogen; Amgen-Roche) at a dose of limiting toxicity. The pancytopenic period is reduced with 5 g/kg/day for 13 days. In all other cycles G-CSF had the introduction of cryopreserved autologous peripheral been given at the same dose from day 7. On days 11, blood progenitor cells (PBPC) in addition to or instead of 12 and 13 the leukaphereses were performed and their bone marrow. 3 PBPC can render possible the optimization products cryopreserved. On day 14 whole blood was colof dose intensity both in single high-dose chemotherapy or lected. The median peak incidence of CFU-GM in multiple cycles of intensified conventional chemo-(granulocyte-macrophage colony-forming unit) in pertherapy.
4
ipheral blood was approximately 50 times the baseline Recently several researchers have reported favorable level. The leukapheresed PBPC were divided into poreffects when unprocessed autologous whole blood rich in tions and reinfused after the fourth, fifth and sixth PBPC (instead of leukapheresed PBPC concentrates) was chemotherapy courses. The support with mobilized transfused to patients following high-dose chemotherapy. whole blood was given after the second and third cycles.
Unprocessed blood can be stored for 24-28 h at room temThe effects of the support of whole blood vs leukapherperature or at 4°C. This method reduces the cost of PBPC esed PBPC on hematopoietic recovery were compared.
collection and avoids the toxicity of DMSO. 2, 5 The use of The best yields of leukaphereses were achieved on day unprocessed whole blood only was such an attractive idea 13 after initiation of the chemotherapy. The mean numthat we tried it with three patients in 1986. 6 /kg). PBPC yields in 450 ml of firm this possibility, too. 5, 7 Chemotherapy followed by the unprocessed whole blood were in some cases not sufadministration of growth factors is an effective way to colficient for good hematopoietic recovery after the EC lect PBPC, but the optimal combination of cytostatics and cycles. Grade 4 leukopenias and thrombocytopenias growth factors is not yet known. 8, 9 Perfect priming, howwere two times higher in cycles with whole blood supever, is very important. In our previous reports we tried port than in cycles with cryopreserved PBPC support.
different PBPC mobilization regimens with a wide range An increase of PBPC harvest can be simply achieved by of cyclophosphamide dosages or combinations of other cytostatics followed by application of G-CSF or GM-CSF at different doses. 10, 11 In our patients with breast cancer the combination of epirubicin plus cyclophosphamide proved Correspondence: Dr M Blaha, II Department of Medicine, Charles Univerto be advantageous. therapeutic cycles. At the same time, the first cycle served programmable freezer (Planer Biomed, Sunbury-onThames, UK) with a controlled rate of freezing (Ϫ1°C/min for mobilization. Towards its end PBPC were harvested by leukapheresis and whole blood was collected on the last to Ϫ90°C, Ϫ5°C/min to Ϫ150°C). After freezing, PBPC were stored in liquid nitrogen at Ϫ196°C. day. In the second and third cycles only whole blood was given for support. Cryopreserved PBPC were used for supThawing was performed in the water bath at 37°C and the suspension was infused into a central venous catheter port in the fourth, fifth and sixth chemotherapy cycles. Then the therapeutic effects of unprocessed whole blood vs directly from the freezing bags (Baxter Fenwal, Deerfield, IL, USA) without removal of the cryoprotectant. leukapheresed PBPC on hematopoietic recovery were compared.
Whole blood collection Patients and methods
Whole blood was collected on day 14 into standard blood collection bags (Japan Medical Supply, Singapore) containThe eligibility criteria for admission to the protocol were:
ing 50 ml of CPDA solution as an anticoagulant. The total (1) Women in 2nd stage breast carcinoma after mastectomy volume of whole blood was 450 ml. The bags were stored with a tumor involving more than 10 axillary lymph nodes.
in a refrigerator at the Tissue Bank at ϩ4°C for 2 days (2) Women with metastatic disease but with no metastases before being reinfused to the patient after the next cycle of in the brain and bone marrow and with no previous chemo-EC chemotherapy. therapy. (3) Women with locally advanced breast carcinoma including the inflammatory breast carcinoma (further criteria according to T4 TNM classification). (4) Flow cytometry and colony assays Performance status 0 or 1 (WHO scale). (5) Women with no previous or concomitant malignancy, with an absence of Mononuclear cells expressing the CD34 ϩ surface memsignificant cardiac disease, with a normal blood cell count brane antigen were quantified by flow cytometry using the (pretreatment neutrophils Ͼ2 ϫ 10 9 /l, platelets Ͼ100 ϫ Con IgG 1-FITC antibody and the CD34 ϩ FITC-conjugated 10 9 /l), with normal basic biochemical parameters. 8G12 antibody (HPCA-2 FITC; Becton Dickinson, MounSixteen consecutive patients fulfilling the eligibility critain View, CA, USA). Cytofluorimetric analysis was perteria completed the study. The mean age was 46 years formed using a FACScan (Becton Dickinson) after lysis (median 48 years, range 32-57). Informed consent was of the erythrocytes with ammonium chloride-EDTA. The obtained from each patient prior to the treatment. minimum event number for each test was 10 000 and the count of CD34 ϩ cells was performed in a wide gate. However, it was possible to exclude the debris and the erythroMobilization procedure and chemotherapeutic regimen cytes by using the forward scatter characteristics CD45 ϩ All patients received six cycles of chemotherapy: epirubicin fluorescence dot plot. Hematopoietic progenitor cells were at a dose of 150 mg/m 2 and cyclophosphamide at a dose determined by CFU-GM colony assays. Isolated purified of 1250 mg/m 2 (EC) on day 1. In the first cycle, 24 h after mononuclear cells were plated at a concentration of 2 ϫ chemotherapy, mobilization was started with subcutaneous 10 5 /ml. The medium consisted of Iscoves modified Dulbecapplication of G-CSF (Roche, Basel, Switzerland) at a dose co's medium 20% supplemented with 10% bovine serum of 5 g/kg/day for the next 13 days. In all remaining cycles albumin, 20% fetal calf serum, 100 g glutamine 3%, G-CSF was given from day 7 after chemotherapy. On days 100 g penicillin ϩ streptomycin, 135 l NaHCO 3 7.5%, 11, 12 and 13 leukaphereses were performed; whole blood recombinant GM-CSF 10 ng/ml and 0.9% methylcellulose. was collected on day 14. The leukapheresed PBPC harvests Aliquots of 1 ml were plated in duplicate in 35 mm Petri were divided into several portions and infused after the dishes. Only aggregates with more than 40 cells were confourth, fifth and sixth therapeutic courses. Mobilized whole sidered colonies and were scored using an inverted blood was given as support after the second and third Olympus OSP-2 microscope after 14 days of CFU-GM cycles.
incubation at 37°C in 5% CO 2 fully humidified atmosphere.
PBPC harvest
Results PBPC were collected by leukaphereses during G-CSF administration. The leukaphereses were performed using an automated COBE Spectra (Lakewood, CO, USA) continuIn the group of 16 treated patients, the mean white blood cell (WBC) count before chemotherapy (cyclophosous blood flow cell separator with the following parameters: blood volume processed:10 000-12 000 ml (median phamide, epirubicin) and G-CSF administration was 5.80 ϫ 10 9 /l (range 2.30-9.20 ϫ 10 9 /l). On day 5 after chemo-11 000 ml) per procedure; inlet flow rate: 60-70 ml/min. We used an original Cobe MNC program software 5.1 with therapy these values increased to 14.90 ϫ 10 9 /l (range 10-26.10 ϫ 10 9 /l) and minimal values after decrease of WBC 'quick start', the inlet: AC ratio was 1:12. PBPC were cryopreserved with 10% dimethylsulfoxide (DMSO) in a stabilappeared by day 8, the mean was 1.40 ϫ 10 9 /l (range 0.60-2.00 ϫ 10 9 /l). Then the leukocyte count recovered and by ization solution containing dextran, sucrose, dextrose and anticoagulants. Human serum albumin was added to a final day 10 was 8.70 ϫ 10 9 /l (range 1.10-42.60 ϫ 10 9 /l). The peak WBC appeared approximately by day 14, and was concentration of 1%. The product was frozen in a Kryo-10 52.70 ϫ 10 9 /l (range 21.10-88.0 ϫ 10 9 /l) (see Figure 1a ). intervals were identical in both groups. The grades of leukopenias in patients supported with whole blood vs leuThe mean number of CD34 ϩ cells in peripheral blood was 3.96 ϫ 10 7 /l (range 1.30-9.20 ϫ 10 7 /l) before adminiskapheresed PBPC were as follows: grade 4 (36%)/(14%), grade 3 (57%)/(73%) and grade 2 (7%)/(13%), respectively. tration of chemotherapy. The first peak we observed on day 4 (mean 7.56 ϫ 10 7 /l, range 0.20-17.40 ϫ 10 7 /l). After a The grades of thrombocytopenia were: grade 4 (29%)/ (11%), grade 3 (21%)/(12%), grade 2 (25%)/(36%), grade decrease with minimal values on day 8 (mean 1.27 ϫ 10 7 /l, range 0.20-2.90 ϫ 10 7 /l), the second peak appeared on day 1 (28%)/(38%) and grade 0 (0%)/(3%), respectively. The incidence of grade 4 leukopenias and thrombocytopenias 14 (mean 64.40 ϫ 10 7 /l, range 31.20-134.40 ϫ 10 7 /l) (Figure 1b) . was more than two times higher with only whole blood support than with cryopreserved PBPC support. The mean number of circulating progenitors CFU-GM in peripheral blood was 2.80 ϫ Peripheral blood progenitor cell harvesting was started needed for their transplantation can be obtained by a single or a few leukaphereses. 2 The optimal time for primitive as soon as there was evidence of a considerable increase in WBC count after the chemotherapy-induced nadir. This blood cell collection is when the leukocyte counts are increasing exponentially after the chemotherapy-induced usually occurred 10 days after application of cytostatics. The number of leukaphereses was three or four, the maxinadir. At the stimulated peak, peripheral blood may contain a mal harvest being achieved on day 13.
In our 16 patients the median number and range of cells PBPC amount sufficient for transplantation without further processing. That was the impulse to revive our original idea collected on day 13 was as follows: 
17,18
Hematopoietic recovery Our previous experience with different methods of priming in breast cancer 10,11 showed the above-mentioned EC The mean value of applied CFU-GM per cycle was 0.51 ϫ 10 5 /kg in the courses supported by whole blood only regimen to be the best. It was well tolerated, even if the drug doses were higher than in so-called standard therapy. and 1.93 ϫ 10 5 /kg in the leukapheresis harvested PBPC supported courses. The applied dose of cytostatics and It could be done on an outpatient basis which is also less troublesome for the patient. Our yields in the leukaphereses after combined EC chemotherapy plus G-CSF were so high that we decided to collect only 450 ml of blood. With this regimen, the median peak incidence of CFU-GM in peripheral blood was 50 times more than the baseline level which compares well with other mobilization regimens.
7, 19, 20 Some authors succeeded in increasing CFU-GM counts up to 120-fold. 2 The mean leukapheresis harvests collected on day 13 were the best and were even better than the cut-off value of CD34
ϩ cells for transplantation (3.50 ϫ 10 6 /kg). 21 The mean number of CFU-GM in the leukaphereses performed 
